Carter B, Mak P, Tao W, Ayoub E, Ostermann L, Huang X, et al. Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics. Blood Cancer J. 2023;13:57 pubmed publisher

Xu Y, Zhang Z, Zhao Y, Zhao C, Shi M, Dong X, et al. TRAPPC1 is essential for the maintenance and differentiation of common myeloid progenitors in mice. EMBO Rep. 2023;24:e55503 pubmed publisher

Manzano Mu xf1 oz A, Yeste J, Ortega M, Mart xed n F, L xf3 pez A, Rosell J, et al. Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy. NPJ Precis Oncol. 2022;6:90 pubmed publisher

Fraser C, Spetz J, Qin X, Presser A, Choiniere J, Li C, et al. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics. Nat Commun. 2022;13:5789 pubmed publisher

Sekar G, Singh G, Qin X, Guibao C, Schwam B, Inde Z, et al. Small molecule SJ572946 activates BAK to initiate apoptosis. iScience. 2022;25:105064 pubmed publisher

Pogacar Z, Groot K, Jochems F, Dos Santos Dias M, Mulero S xe1 nchez A, Morris B, et al. Genetic and compound screens uncover factors modulating cancer cell response to indisulam. Life Sci Alliance. 2022;5: pubmed publisher

Pan R, Ryan J, Pan D, Wucherpfennig K, Letai A. Augmenting NK cell-based immunotherapy by targeting mitochondrial apoptosis. Cell. 2022;185:1521-1538.e18 pubmed publisher

Hemming M, Bhola P, Loycano M, Anderson J, Taddei M, Doyle L, et al. Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clin Cancer Res. 2022;28:2397-2408 pubmed publisher

Deng J, Tian A, Pan H, Sauvat A, Leduc M, Liu P, et al. Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. Cell Death Dis. 2021;12:978 pubmed publisher

Manzano Mu xf1 oz A, Alcon C, Men xe9 ndez P, Ram xed rez M, Seyfried F, Debatin K, et al. MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia. Front Cell Dev Biol. 2021;9:695225 pubmed publisher

Liang Z, Zhang Q, Zhang Z, Sun L, Dong X, Li T, et al. The Development and Survival of Thymic Epithelial Cells Require TSC1-Dependent Negative Regulation of mTORC1 Activity. J Immunol. 2021;207:2039-2050 pubmed publisher

Victorino F, Bigley T, Park E, Yao C, Benoit J, Yang L, et al. HIF1α is required for NK cell metabolic adaptation during virus infection. elife. 2021;10: pubmed publisher

Alcon C, G xf3 mez Tejeda Za xf1 udo J, Albert R, Wagle N, Scaltriti M, Letai A, et al. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Cells. 2021;10: pubmed publisher

Potter D, Du R, Bhola P, Bueno R, Letai A. Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer. Cell Death Dis. 2021;12:741 pubmed publisher

Olesinski E, Bhatt S. Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models. STAR Protoc. 2021;2:100461 pubmed publisher

Ca xf1 edo E, Totten S, Ahn R, Savage P, MacNeil D, Hudson J, et al. p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors. JCI Insight. 2021;6: pubmed publisher

Dhimolea E, de Matos Simoes R, Kansara D, Al Khafaji A, Bouyssou J, Weng X, et al. An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell. 2021;39:240-256.e11 pubmed publisher

Bhatt S, Pioso M, Olesinski E, Yilma B, Ryan J, Mashaka T, et al. Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Cancer Cell. 2020;38:872-890.e6 pubmed publisher

Alcon C, Manzano Muñoz A, Prada E, Mora J, Soriano A, Guillén G, et al. Sequential combinations of chemotherapeutic agents with BH3 mimetics to treat rhabdomyosarcoma and avoid resistance. Cell Death Dis. 2020;11:634 pubmed publisher

Meyer L, Huang B, Delgado Martín C, Roy R, Hechmer A, Wandler A, et al. Glucocorticoids paradoxically facilitate steroid resistance in T cell acute lymphoblastic leukemias and thymocytes. J Clin Invest. 2020;130:863-876 pubmed publisher

Ramsey H, Fischer M, Lee T, Gorska A, Arrate M, Fuller L, et al. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia. Cancer Discov. 2018;8:1566-1581 pubmed publisher

Jenson J, Ryan J, Grant R, Letai A, Keating A. Epistatic mutations in PUMA BH3 drive an alternate binding mode to potently and selectively inhibit anti-apoptotic Bfl-1. elife. 2017;6: pubmed publisher